Drug
Marizomib clinical trials
Also written NPI-0052.
- studies test it
- 10
- open now
- 0
- in phase 3
- 1
- first study started
- 2006
How studies write it
Studies that test it under each name
Development codes
Other names
Combined with it in one product
Studies by the year they started
10 studies that test it; most in 2007 (2)
| Year | Studies |
|---|---|
| 2006 | 1 |
| 2007 | 2 |
| 2008 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2018 | 2 |
| 2020 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 5
- Phase 2
- 5
- Phase 3
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 7 · Other 3
Celgene (6) · European Organisation for Research and Treatment of Cancer - EORTC (1) · Aadi Bioscience, Inc. (1) · National Cancer Institute (NCI) (1) · Dana-Farber Cancer Institute (1)
Often tested with
Tested in the same studies.
Bevacizumab (2) · Pomalidomide (2) · Dexamethasone (2) · Sirolimus Albumin-bound Nanoparticles (1) · Temozolomide (1) · Lomustine (1)
Studies
Open first, then newest update. How each study uses marizomib is read from its arms, and is right about nine times in ten.
Testing it · 10
- A Phase III Trial of With Marizomib in Patients With Newly Diagnosed GlioblastomaCompletedPhase 3European Organisation for Research and Treatment of Cancer - EORTCNCT03345095Written as Marizomib
- Marizomib Central Nervous System (CNS)WithdrawnPhase 2Dana-Farber Cancer InstituteNCT05050305Written as Marizomib
- Nab-sirolimus in Recurrent High Grade Glioma and Newly Diagnosed GlioblastomaCompletedPhase 2Aadi Bioscience, Inc.NCT03463265Written as nab-sirolimus + marizomib (MRZ)
- Marizomib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial, and Spinal Cord EpendymomaTerminatedPhase 2National Cancer Institute (NCI)NCT03727841Written as Marizomib
- Stage 1: Marizomib + Bevacizumab in WHO Gr IV GBM; Stage 2: Marizomib Alone; Stage 3: Combination of Marizomib and BevacizumabCompletedPhase 1/2CelgeneNCT02330562Written as MRZ
- Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple MyelomaCompletedPhase 2CelgeneNCT00461045Written as MRZ 0.5 mg/m^2
- NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or LymphomaCompletedPhase 1CelgeneNCT00667082Written as NPI-0052 (marizomib) + vorinostat
- Phase 1 Clinical Trial of NPI-0052 in Patients With Advanced MalignanciesCompletedPhase 1CelgeneNCT00629473Written as NPI-0052 on Days 1, 8, 15 every 28 days
- Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple MyelomaCompletedPhase 1CelgeneNCT02103335Written as marizomib
- Phase 1 Clinical Trial of NPI-0052 in Patients With Advanced Solid Tumor Malignancies or Refractory LymphomaCompletedPhase 1CelgeneNCT00396864Written as NPI-0052
Given in every arm · 2 — marizomib is usual care beside what is tested
Codes
What other systems call marizomib · ClinicalTrials.gg INT004545
- MeSH (NLM) C475865marizomibConfirmed NLM, Wikidata
- UNII (FDA) 703P9YDP7FMARIZOMIBConfirmed FDA, NLM, Wikidata
- Wikidata Q7404722marizomibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C64634MarizomibOne source FDA
- DrugBank DB11762One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C475865 | marizomib | Confirmed NLM, Wikidata |
| UNII (FDA) | 703P9YDP7F | MARIZOMIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q7404722 | marizomib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C64634 | Marizomib | One source FDA |
| DrugBank | DB11762 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.